Methimazole-Induced Remission Rates in Pediatric Graves’ Disease: a Systematic Review

in European Journal of Endocrinology
View More View Less
  • 1 J van Lieshout, Pediatric Endocrinology, Emma Childrens' Hospital UMC, Amsterdam, Netherlands
  • 2 C Mooij, Emma Children's Hospital, University of Amsterdam, Amsterdam, 1105 AZ, Netherlands
  • 3 A van Trotsenburg, Pediatric Endocrinology, Amsterdam UMC - Locatie AMC, Amsterdam, 1105AZ, Netherlands
  • 4 N Zwaveling-Soonawala, Pediatric Endocrinology, Amsterdam UMC - Locatie AMC, Amsterdam, 1100 DD, Netherlands

Correspondence: Nitash Zwaveling-Soonawala, Email: n.zwaveling@amsterdamumc.nl
Restricted access

Objective: Comparison of studies on remission rates in pediatric Graves’ disease is complicated by lack of uniformity in treatment protocols, remission definition, and follow-up duration. We performed a systematic review on remission rates in pediatric Graves’ disease and attempted to create uniformity by recalculating remission rates based on an intention-to-treat analysis.

Methods: PubMed and Embase were searched in August 2020 for studies on patients with Graves’ disease (i) 2 to 18 years of age, (ii) initially treated with methimazole or carbimazole for at least 18 months, (iii) with a follow-up duration of at least one year after cessation of methimazole or carbimazole. All reported remission rates were recalculated using an intention-to-treat analysis.

Results: Of 1,890 articles, 29 articles consisting of 24 patient cohorts, were included with a total of 3,057 patients (82.6% female). Methimazole or carbimazole was initially prescribed in 2,864 patients (93.7%). Recalculation based on intention-to-treat analysis resulted in an overall remission rate of 28.8% (829/2,880). Pooled remission rates based on treatment duration were 23.7%, 31.0%, 43.7%, and 75% after respectively 1.5-2.5 years, 2.5-5 years, 5-6 years (two studies), and 9 years (single study) treatment duration. Occurrence of adverse events was 419 in 2,377 patients (17.6%), with major side effects in 25 patients (1.1%).

Conclusions: Using a standardized calculation the overall remission rate in methimazole treated pediatric GD is 28.8%. A few small studies indicate that longer treatment increases the remission rate. However, evidence is limited and further research is necessary to investigate the efficacy of longer treatment durations.

 

     European Society of Endocrinology

Sept 2018 onwards Past Year Past 30 Days
Abstract Views 123 123 123
Full Text Views 9 9 9
PDF Downloads 11 11 11